In a crossover trial of 25 active adults with type 1 diabetes on insulin pumps, ultra-rapid lispro attenuated the fall in glucose during exercise vs lispro with both 50% and 100% basal rate reductions; hypoglycaemia was numerically lower (6% vs 16%).
RCTn = 25
Leohr et al. Ultra-Rapid Lispro Has an Improved Pharmacokinetic Profile for Exercise Compared With Lispro, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion